SOM230 LAR in patients with metastatic carcinoid tumors (01)

• Research type

  Research Study

• Full title

  Clinical Trial Protocol CSOM230C2303 A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues

• IRAS ID

  7300

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2007-000739-25

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  The purpose of this study is to compare the long-term efficacy of pasireotide LAR vs. octreotide LAR in controlling diarrhoea and flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by the maximum approved doses of somatostatin analogues. Study is sponsored by Novartis.

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  08/H0504/170

• Date of REC Opinion

  3 Dec 2008

• REC opinion

  Further Information Favourable Opinion